ES2093078T3 - Compuesto farmaceuticamente activo sobre el snc. - Google Patents

Compuesto farmaceuticamente activo sobre el snc.

Info

Publication number
ES2093078T3
ES2093078T3 ES91304935T ES91304935T ES2093078T3 ES 2093078 T3 ES2093078 T3 ES 2093078T3 ES 91304935 T ES91304935 T ES 91304935T ES 91304935 T ES91304935 T ES 91304935T ES 2093078 T3 ES2093078 T3 ES 2093078T3
Authority
ES
Spain
Prior art keywords
elevated
hydrogen
halo
cns
nitro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91304935T
Other languages
English (en)
Spanish (es)
Inventor
Michael John Leach
Malcolm Stuart Nobbs
Ramachandran Iyer
Clive Leonard Yeates
Philip Alan Skone
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Application granted granted Critical
Publication of ES2093078T3 publication Critical patent/ES2093078T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C07D239/49—Two nitrogen atoms with an aralkyl radical, or substituted aralkyl radical, attached in position 5, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Liquid Crystal Substances (AREA)
  • Paper (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ES91304935T 1990-06-01 1991-05-31 Compuesto farmaceuticamente activo sobre el snc. Expired - Lifetime ES2093078T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909012316A GB9012316D0 (en) 1990-06-01 1990-06-01 Pharmacologically active cns compounds

Publications (1)

Publication Number Publication Date
ES2093078T3 true ES2093078T3 (es) 1996-12-16

Family

ID=10676964

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91304935T Expired - Lifetime ES2093078T3 (es) 1990-06-01 1991-05-31 Compuesto farmaceuticamente activo sobre el snc.

Country Status (25)

Country Link
EP (2) EP0679645A1 (online.php)
JP (1) JPH06340634A (online.php)
KR (1) KR920000733A (online.php)
AT (1) ATE141263T1 (online.php)
AU (2) AU652753B2 (online.php)
CA (1) CA2043640A1 (online.php)
CZ (1) CZ281070B6 (online.php)
DE (1) DE69121317T2 (online.php)
DK (1) DK0459819T3 (online.php)
ES (1) ES2093078T3 (online.php)
FI (1) FI912623A7 (online.php)
GB (1) GB9012316D0 (online.php)
GR (1) GR3021237T3 (online.php)
HU (2) HUT58707A (online.php)
IE (1) IE911861A1 (online.php)
IL (2) IL113599A (online.php)
MY (2) MY109958A (online.php)
NO (1) NO180375C (online.php)
NZ (3) NZ238360A (online.php)
PL (2) PL170373B1 (online.php)
PT (1) PT97827B (online.php)
RU (1) RU2091374C1 (online.php)
SK (1) SK278444B6 (online.php)
TW (1) TW224460B (online.php)
ZA (1) ZA914165B (online.php)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI895821A7 (fi) * 1988-12-07 1990-06-08 The Wellcome Foundation Ltd Farmaseuttisesti aktivisia CNS-yhdisteitä
US5629016A (en) * 1991-01-30 1997-05-13 Glaxo Wellcome Inc. Water-dispersible tablets
FI20021701L (fi) * 1991-01-30 2002-09-24 Wellcome Found Veteen dispergoituvia tabletteja
GB9215908D0 (en) * 1992-07-27 1992-09-09 Wellcome Found Water dispersible tablets
GB9226377D0 (en) * 1992-12-18 1993-02-10 Babbedge Rachel C Pharmaceutical compositions
JPH08504798A (ja) * 1992-12-18 1996-05-21 ザ ウエルカム ファウンデーション リミテッド 酵素阻害薬としての，ピリミジン，ピリジン，プテリジノンおよびインダゾール誘導体
US5698226A (en) * 1993-07-13 1997-12-16 Glaxo Wellcome Inc. Water-dispersible tablets
GB9319341D0 (en) * 1993-09-17 1993-11-03 Wellcome Found Novel process
FR2741879A1 (fr) * 1995-12-05 1997-06-06 Esteve Labor Dr Derives de fluorophenyl-triazines et pyrimidines, leur preparation et leur application en tant que medicament
US6440965B1 (en) 1997-10-15 2002-08-27 Krenitsky Pharmaceuticals, Inc. Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
DE19751949A1 (de) * 1997-11-24 1999-05-27 Bayer Ag Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration
GB9726987D0 (en) 1997-12-22 1998-02-18 Glaxo Group Ltd Compounds
US6583148B1 (en) 1999-04-08 2003-06-24 Krenitsky Pharmaceuticals, Inc. Neurotrophic substituted pyrimidines
DE19918325A1 (de) 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
ES2283315T3 (es) 1999-09-16 2007-11-01 Tanabe Seiyaku Co., Ltd. Compuestos ciclicos de 6 miembros que contienen nitrogeno aromatico.
ATE293962T1 (de) * 2000-02-25 2005-05-15 Hoffmann La Roche Adenosin-rezeptor modulatoren
KR100711042B1 (ko) 2000-04-28 2007-04-24 다나베 세이야꾸 가부시키가이샤 환상 화합물
US7273868B2 (en) 2000-04-28 2007-09-25 Tanabe Seiyaku Co., Ltd. Pyrazine derivatives
JP5154728B2 (ja) * 2000-07-24 2013-02-27 クレニツキー・ファーマシューティカルズ，インコーポレイテッド 神経栄養活性を有する置換５−アルキニルピリミジン
WO2002068419A1 (en) 2001-02-26 2002-09-06 Tanabe Seiyaku Co., Ltd. Pyridopyrimidine or naphthyridine derivative
AU2003203148A1 (en) * 2002-02-05 2003-09-02 High Point Pharmaceuticals, Llc Novel aryl- and heteroarylpiperazines
TW200637556A (en) * 2005-01-31 2006-11-01 Basf Ag Substituted 5-phenyl pyrimidines I in therapy
EP2386554A1 (en) 2005-07-04 2011-11-16 High Point Pharmaceuticals, LLC Compounds active at the histamine H3 receptor
JP2009537596A (ja) 2006-05-23 2009-10-29 ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー ６−（４−シクロプロピルピペリジン−１−イル）−２’−メチル−［３，４’］−ビピリジン及びその医薬としての使用
EP2079732B9 (en) 2006-05-29 2012-03-21 High Point Pharmaceuticals, LLC 3- (1, 3-benz0di0x0l-5-yl) -6- (4-cyclopropylpiperazin-1-yl) -pyridazine, its salts and solvates and its use as histamine h3 receptor antagonist
EP2014656A3 (en) 2007-06-11 2011-08-24 High Point Pharmaceuticals, LLC New heteocyclic h3 antagonists
EA031153B1 (ru) 2011-06-10 2018-11-30 Мерк Патент Гмбх Применение пиримидиновых соединений с btk ингибирующей активностью
EP3094627B1 (en) 2014-01-17 2018-08-22 Novartis AG 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and and compositions thereof for inhibiting the activity of shp2
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
AU2017283769B2 (en) 2016-06-14 2019-08-15 Novartis Ag Compounds and compositions for inhibiting the activity of SHP2
EP3568204B1 (en) 2017-01-10 2023-08-30 Novartis AG Pharmaceutical combination comprising an alk inhibitor and an shp2 inhibitor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE518622A (online.php) *
FI895821A7 (fi) * 1988-12-07 1990-06-08 The Wellcome Foundation Ltd Farmaseuttisesti aktivisia CNS-yhdisteitä
US5136080A (en) * 1989-12-04 1992-08-04 Burroughs Wellcome Co. Nitrile compounds

Also Published As

Publication number Publication date
IL98330A (en) 1996-10-31
HUT58707A (en) 1992-03-30
KR920000733A (ko) 1992-01-29
AU652753B2 (en) 1994-09-08
IL113599A0 (en) 1995-08-31
NO180375C (no) 1997-04-09
HU211649A9 (en) 1995-12-28
IL98330A0 (en) 1992-06-21
RU2091374C1 (ru) 1997-09-27
CS164391A3 (en) 1992-02-19
JPH06340634A (ja) 1994-12-13
NZ272001A (en) 1997-03-24
MY109958A (en) 1997-10-31
TW224460B (online.php) 1994-06-01
EP0459819A2 (en) 1991-12-04
NO912100D0 (no) 1991-05-31
PL170373B1 (pl) 1996-12-31
FI912623A7 (fi) 1991-12-02
DE69121317T2 (de) 1997-01-02
CZ281070B6 (cs) 1996-06-12
EP0459819B1 (en) 1996-08-14
SK278444B6 (en) 1997-05-07
EP0679645A1 (en) 1995-11-02
DK0459819T3 (da) 1996-09-02
PT97827A (pt) 1992-03-31
IE911861A1 (en) 1991-12-04
EP0459819A3 (en) 1992-03-11
AU7809791A (en) 1991-12-05
AU6745594A (en) 1994-09-15
PT97827B (pt) 1998-10-30
CA2043640A1 (en) 1991-12-02
GR3021237T3 (en) 1997-01-31
MY136248A (en) 2008-08-29
PL166656B1 (pl) 1995-06-30
NO912100L (no) 1991-12-02
IL113599A (en) 1997-09-30
HU911826D0 (en) 1991-12-30
ZA914165B (en) 1993-03-01
GB9012316D0 (en) 1990-07-18
NZ248501A (en) 1997-03-24
FI912623A0 (fi) 1991-05-31
NZ238360A (en) 1997-03-24
DE69121317D1 (de) 1996-09-19
AU680252B2 (en) 1997-07-24
NO180375B (no) 1996-12-30
ATE141263T1 (de) 1996-08-15

Similar Documents

Publication Publication Date Title
NO307047B1 (no) Nye hydroksyetylaminosulfonamider som er nyttige som retrovirale proteasehemmere, farmasøytisk preparat inneholdende slike, og anvendelse derav
SV1998000029A (es) Compuestos de pirazina ref. pg3186
ES2095842T3 (es) Compuestos farmacologicamente activos sobre el snc
CO4290353A1 (es) Agonistas de estrogeno
ES2118710T3 (es) Nuevos inhibidores de peptidasa.
MX9300735A (es) Derivados de bencimidazolilo, medicamentos que contienen estos compuestos y procedimientos para su preparacion.
ES2129679T3 (es) Derivados que contienen el grupo amidino, utiles como inhibidores de la sintasa de oxido nitrico.
BR9407317A (pt) Derivados vasoconstritores da diidrobenzopirana
NO996208D0 (no) Nye 2-(iminometyl)amino- fenylderivater, fremstilling og blandinger derav, samt anvendelse som legemiddel
ES2067874T3 (es) Derivados de acetamida.
ES2067822T3 (es) Inhibidores de la fosfolipasa a2 isoprenoide y preparaciones que los contienen.
ES2077399T3 (es) Derivados de poli-4-aminopirrol-2-carboxiamida, procedimientos para su preparacion y composiciones farmaceuticas que los contienen.
CO4970807A1 (es) Compuestos de indol 2,3 sustituidos como agentes anti-infla matorios y analgesicos
ES2104841T3 (es) Fosfono-aminoacidos bencimidazolicos.
MX9305510A (es) Compuestos para el tratamiento o profilaxis de desordenes gastrointestinales, cardiovasculares y del sistema nervioso central, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
ES2070002T3 (es) Composiciones terapeuticas a base de derivados de 1,2-ditiol-3-tiona.
ES2056073T3 (es) Aril-aralquil-eteres, procedimientos para su preparacion y composicion farmaceutica que los comprende.
ES2116612T3 (es) Nuevas bis-naftalimidas para el tratamiento del cancer.
ES2188908T3 (es) Derivados de cis-3,4-cromano utiles para la prevencion o tratamiento de sindromes relacionados con el estrogenos.
ES2100396T3 (es) Derivados de 17-(3-furil)- y 17-(4-piridazinil)-5beta,14beta-androstano activos sobre el sistema cardiovascular, procesos para su preparacion y composiciones farmaceuticas que los contienen.
ES2191683T3 (es) Procedimiento para preparar inhibidores de la proteasa del vih.
ES2087782T3 (es) Procedimiento para la fabricacion de aductos liquidos de aminas con amidas que contienen grupos fluorados.
ES2055651B1 (es) Procedimiento para la obtencion de nuevas amidinas derivadas de 3-aminoetilindoles.
ES2054833T3 (es) Derivados tioformamida.
FR73098E (fr) Nouveaux dérivés de l'iminodibenzyle substitués à l'azote par une chaîne pipérazinique

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 459819

Country of ref document: ES